Hisun-Pfizer hiring drive heavy on manufacturing; JV invests in Sri Lanka plant;

> Hisun-Pfizer, the new joint venture between Pfizer ($PFE) and Zhejiang Hisun Pharmaceutical, intends to more than double the size of its workforce by the end of the year by hiring 600 employees, mostly in manufacturing. Story

> PC Pharma, a Sri Lankan drug importer and distributor, says it is investing $2 million in a joint venture with Square Pharmaceuticals of Bangladesh to build a drug manufacturing plant on the island next year. Story

> The FDA is warning consumers to stop taking a product manufactured in El Salvador for infectious diarrhea and found in some stores in the U.S. because it contains the prescription drug ingredient, chloramphenicol, oral forms of which were withdrawn from the U.S. in July. Release

> A recent conference in Germany on geriatrics medicine suggested that drugmakers bring new formulations to market that are easier to swallow and easier to identify for an aging population. Story

> Procter & Gamble ($PG) has given its Prilosec heartburn pill a new flavor, wildberry. Story

And Finally... Ton Büchner, who became CEO of chemical giant and API maker AkzoNobel in April, has been ordered to take a leave of absence until mid-October to deal with fatigue. Story

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.